Glenmark Pharma: 130% Profit Surge – Is This the Biotech Phoenix?

At a Glance

Glenmark Pharmaceuticals is back in the headlines with a Q4 PAT of ₹1,047 Cr after FY24’s painful loss of ₹1,434 Cr. Riding on the AbbVie $2B licensing deal and a strong oncology portfolio, the stock sits at ₹2,068 with a P/E of 44. Investors are suddenly treating Glenmark less like a generic maker and more like a biotech lottery ticket. But can this phoenix fly consistently or will the FDA ground it again?

Introduction

Once just another generic maker with middling margins, Glenmark has reinvented itself as a specialty and biotech contender. Over 80 countries, multiple segments (Generics, Specialty, OTC), and now a growing oncology franchise make it a serious player. But, FDA warning letters and uneven profit history remind us this stock isn’t for the faint of heart.

2025 so far? Immuno-oncology launches, blockbuster licensing with AbbVie, and yes, a USFDA OAI classification at Indore – because Glenmark’s thrill ride always includes a sharp turn.

Business Model (WTF Do They Even Do?)

• Generics: 15th largest in the US, strong European presence.
• Specialty Drugs: Oncology (Tevimbra, Brukinsa), dermatology, respiratory.
• Biologics & Licensing: ISB 2001 licensed to AbbVie for $700M upfront.
• OTC: Limited but growing presence.

Revenue mix is 40% generics, 35% specialty, 25% emerging markets. Margins thrive where the science is premium (oncology), not where the competition is cutthroat (US generics).

Financials Overview

Commentary: Sales up 13%, margins rebounded to 18%, profits back